Development of a 2-Plex Luminex-Based Competitive Immunoassay to Quantify Neutralizing Antibodies Induced by Virus-Like Particles for Human Papillomavirus 16 and 18

Human papillomavirus (HPV) L1 virus-like particles (VLPs) were proven an effective vaccine candidate to prevent against HPV-16 and -18 infections. In order to evaluate the potency of our produced HPV-16 and -18 L1 VLPs-based vaccine candidates, also to quantify neutralizing antibodies induced by the...

Full description

Bibliographic Details
Main Authors: Pin Lv, Hongmei Zhu, Hongfang Wang, George Wang
Format: Article
Language:English
Published: Hindawi Limited 2011-01-01
Series:Journal of Biomedicine and Biotechnology
Online Access:http://dx.doi.org/10.1155/2011/272806
id doaj-f18e5f5ba1a44e9fbca74b9da4a915ff
record_format Article
spelling doaj-f18e5f5ba1a44e9fbca74b9da4a915ff2020-11-25T01:35:45ZengHindawi LimitedJournal of Biomedicine and Biotechnology1110-72431110-72512011-01-01201110.1155/2011/272806272806Development of a 2-Plex Luminex-Based Competitive Immunoassay to Quantify Neutralizing Antibodies Induced by Virus-Like Particles for Human Papillomavirus 16 and 18Pin Lv0Hongmei Zhu1Hongfang Wang2George Wang3Analytical Science & Formulation Department, Shanghai Zerun Biotechnology Co., Ltd. and Genor Biopharma Co., Ltd., 1399 Zhangheng Road, Zhangjiang, Shanghai 201203, ChinaAnalytical Science & Formulation Department, Shanghai Zerun Biotechnology Co., Ltd. and Genor Biopharma Co., Ltd., 1399 Zhangheng Road, Zhangjiang, Shanghai 201203, ChinaAnalytical Science & Formulation Department, Shanghai Zerun Biotechnology Co., Ltd. and Genor Biopharma Co., Ltd., 1399 Zhangheng Road, Zhangjiang, Shanghai 201203, ChinaAnalytical Science & Formulation Department, Shanghai Zerun Biotechnology Co., Ltd. and Genor Biopharma Co., Ltd., 1399 Zhangheng Road, Zhangjiang, Shanghai 201203, ChinaHuman papillomavirus (HPV) L1 virus-like particles (VLPs) were proven an effective vaccine candidate to prevent against HPV-16 and -18 infections. In order to evaluate the potency of our produced HPV-16 and -18 L1 VLPs-based vaccine candidates, also to quantify neutralizing antibodies induced by them, a 2-plex Luminex-based competitive immunoassay was developed. Unlike the published paper, the no-biotin conjugated neutralizing mAbs spiked normal human serum (NHS) was used for standard curve preparation, while phycoerythrin (PE) was not labeled directly to neutralizing mAbs for signaling. After the coupling optimization of VLPs to microspheres and the neutralizing mAbs biotinylation, the 2-plex standard curve was prepared with good fit and high dynamic range. In addition, no cross-reactivity was also confirmed. The 2-plex Luminex-based immunoassay represents good potential not only for vaccine candidate's evaluation but also for its further clinical use.http://dx.doi.org/10.1155/2011/272806
collection DOAJ
language English
format Article
sources DOAJ
author Pin Lv
Hongmei Zhu
Hongfang Wang
George Wang
spellingShingle Pin Lv
Hongmei Zhu
Hongfang Wang
George Wang
Development of a 2-Plex Luminex-Based Competitive Immunoassay to Quantify Neutralizing Antibodies Induced by Virus-Like Particles for Human Papillomavirus 16 and 18
Journal of Biomedicine and Biotechnology
author_facet Pin Lv
Hongmei Zhu
Hongfang Wang
George Wang
author_sort Pin Lv
title Development of a 2-Plex Luminex-Based Competitive Immunoassay to Quantify Neutralizing Antibodies Induced by Virus-Like Particles for Human Papillomavirus 16 and 18
title_short Development of a 2-Plex Luminex-Based Competitive Immunoassay to Quantify Neutralizing Antibodies Induced by Virus-Like Particles for Human Papillomavirus 16 and 18
title_full Development of a 2-Plex Luminex-Based Competitive Immunoassay to Quantify Neutralizing Antibodies Induced by Virus-Like Particles for Human Papillomavirus 16 and 18
title_fullStr Development of a 2-Plex Luminex-Based Competitive Immunoassay to Quantify Neutralizing Antibodies Induced by Virus-Like Particles for Human Papillomavirus 16 and 18
title_full_unstemmed Development of a 2-Plex Luminex-Based Competitive Immunoassay to Quantify Neutralizing Antibodies Induced by Virus-Like Particles for Human Papillomavirus 16 and 18
title_sort development of a 2-plex luminex-based competitive immunoassay to quantify neutralizing antibodies induced by virus-like particles for human papillomavirus 16 and 18
publisher Hindawi Limited
series Journal of Biomedicine and Biotechnology
issn 1110-7243
1110-7251
publishDate 2011-01-01
description Human papillomavirus (HPV) L1 virus-like particles (VLPs) were proven an effective vaccine candidate to prevent against HPV-16 and -18 infections. In order to evaluate the potency of our produced HPV-16 and -18 L1 VLPs-based vaccine candidates, also to quantify neutralizing antibodies induced by them, a 2-plex Luminex-based competitive immunoassay was developed. Unlike the published paper, the no-biotin conjugated neutralizing mAbs spiked normal human serum (NHS) was used for standard curve preparation, while phycoerythrin (PE) was not labeled directly to neutralizing mAbs for signaling. After the coupling optimization of VLPs to microspheres and the neutralizing mAbs biotinylation, the 2-plex standard curve was prepared with good fit and high dynamic range. In addition, no cross-reactivity was also confirmed. The 2-plex Luminex-based immunoassay represents good potential not only for vaccine candidate's evaluation but also for its further clinical use.
url http://dx.doi.org/10.1155/2011/272806
work_keys_str_mv AT pinlv developmentofa2plexluminexbasedcompetitiveimmunoassaytoquantifyneutralizingantibodiesinducedbyviruslikeparticlesforhumanpapillomavirus16and18
AT hongmeizhu developmentofa2plexluminexbasedcompetitiveimmunoassaytoquantifyneutralizingantibodiesinducedbyviruslikeparticlesforhumanpapillomavirus16and18
AT hongfangwang developmentofa2plexluminexbasedcompetitiveimmunoassaytoquantifyneutralizingantibodiesinducedbyviruslikeparticlesforhumanpapillomavirus16and18
AT georgewang developmentofa2plexluminexbasedcompetitiveimmunoassaytoquantifyneutralizingantibodiesinducedbyviruslikeparticlesforhumanpapillomavirus16and18
_version_ 1725066521372262400